- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
- Interventions
- Fludarabine, Busulfan, GVHD Prophylaxis, Gemtuzumab Ozogamicin, Anti-Thymocyte Globulin, Isotretinoin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 185
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Not listed
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin, Sebum Deficiency
- Interventions
- Topical Product: Almond Oil, Topical Product: Almond oil augmented with 0.5% Vitamin E, Topical Product: 0.025% Tretinoin oil augmented with castor oil
- Other
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Leukemia
- Interventions
- arsenic trioxide, cytarabine, daunorubicin hydrochloride, mercaptopurine, methotrexate, tretinoin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 5 Years to 74 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 3 more
- Conditions
- Acne
- Interventions
- Duac, Ziana gel
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Mason, Ohio
- Conditions
- Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA, Acute Promyelocytic Leukemia
- Interventions
- QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA
- Drug
- Lead sponsor
- Quetzal Therapeutics
- Industry
- Eligibility
- 18 Years to 71 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Duarte, California • Irvine, California + 14 more
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- dasatinib (SPRYCEL), all trans retinoic acid (VESANOID)
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acne Vulgaris
- Interventions
- Tretinoin Facial Gel, Adapalene/Benzoyl Peroxide Facial Gel
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Broomall, Pennsylvania
- Conditions
- Drug Toxicity, Lung Cancer
- Interventions
- 13-cis retinoic acid, Tocopherol
- Drug · Dietary Supplement
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2005
- U.S. locations
- 4
- States / cities
- Denver, Colorado
- Conditions
- Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 30 Years
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- dexamethasone, isotretinoin
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 18
- States / cities
- Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
- Conditions
- Acne Vulgaris
- Interventions
- Retin-A Micro 0.04% facial acne treatment, Vehicle control
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 9 Years to 11 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 12
- States / cities
- Encino, California • San Diego, California • Miami, Florida + 9 more
- Conditions
- Non-melanoma Skin Cancer
- Interventions
- UAB30, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neuroblastoma
- Interventions
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Months and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- Tretinoin and Arsenic Trioxide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Evanston, Illinois • Bethesda, Maryland + 7 more
- Conditions
- Myeloma
- Interventions
- Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myelodysplastic Syndromes
- Interventions
- decitabine, tretinoin, DNA methylation analysis, cytogenetic analysis, microarray analysis, flow cytometry, immunohistochemistry staining method
- Drug · Genetic · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine, All-Trans Retinoic Acid (ATRA), Midostaurin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neuroblastoma
- Interventions
- 3F8 monoclonal antibody and 13-cis-Retinoic Acid
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Months and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukaemia, Myelocytic, Acute
- Interventions
- GSK2879552, ATRA
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • New York, New York • The Bronx, New York + 1 more
- Conditions
- Brain Tumors
- Interventions
- temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Lihue, Hawaii + 13 more
- Conditions
- Collagen Fibril Alteration
- Interventions
- Tretinoin cream 0.1%
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Irvine, California